Terriou P, Auquier P, Chabert-Orsini V, Chinchole J M, Cravello L, Giorgetti C, Halfon P, Salzmann J, Roulier R
Institut de Médecine de la Reproduction, Marseille, France.
Hum Reprod. 2005 Oct;20(10):2838-43. doi: 10.1093/humrep/dei119. Epub 2005 Jun 24.
Since 2001, French law has permitted the use of assisted reproductive technology in human immunodeficiency virus (HIV)-1 infected women under strict conditions. This report describes a preliminary series of seropositive women who underwent assisted reproduction treatment at our facility. To minimize contamination of culture media, equipment, and therefore of male gametes and embryos, we chose to perform ICSI in all cases. The outcome of ICSI was compared with the outcome in an age-matched group of non-HIV-1-infected women. Since several previous reports have indicated that HIV infection may be associated with a decrease in spontaneous fertility, our goal was also to assess the fertility status of the HIV-1-infected women entering our ICSI programme.
The French law governing the use of assisted reproduction protocols in HIV-1-infected women was strictly applied. The inclusion criteria were absence of ongoing disease, CD4((+)) count >200 cells/mm(3), and stable HIV-1 RNA level. Since mean age at the time of ICSI was higher in HIV-1-infected women than in the overall group of non-HIV-infected women, we compared outcome data in HIV-1-infected women (group I) to a group of non-HIV-1-infected women matched with regard to age and follicle retrieval period (group II) as well as to the overall group of women who underwent ICSI at our institution (group III).
A total of 66 ovarian stimulations was performed in 29 HIV-1-infected-infected women. The percentage of cancelled cycles was higher in infected women than in matched controls (15.2 versus 4.9%, P < 0.05). The duration of ovarian stimulation (13.3 versus 11.7 days, P < 0.05) and amount of recombinant FSH injected (2898 versus 2429 IU, P < 0.001) were also higher in infected women. The number of retrieved oocytes, mature oocytes, and embryos obtained as well as embryo quality was similar in all groups. The fertilization rate was higher in infected women than in matched controls (67 versus 60%, P < 0.01). The pregnancy rate was not significantly different between groups I and II (16.1 versus 19.6%) in spite of the fact that the number of embryos transferred was purposefully restricted in the HIV-1-infected group to minimize multiple pregnancy (2.0 versus 2.4, not significant).
The results of this preliminary series of ICSI cycles in HIV-1-infected women indicate that optimal ovarian stimulation is slightly more difficult to achieve than in matched seronegative women. However, when criteria for oocyte retrieval were fulfilled, ICSI results were similar to those of age-matched controls.
自2001年以来,法国法律允许在严格条件下对感染人类免疫缺陷病毒(HIV)-1的女性使用辅助生殖技术。本报告描述了在我们机构接受辅助生殖治疗的一系列血清学阳性女性的初步情况。为了尽量减少培养基、设备以及因此减少雄配子和胚胎的污染,我们选择在所有病例中进行卵胞浆内单精子注射(ICSI)。将ICSI的结果与年龄匹配的未感染HIV-1女性组的结果进行了比较。由于之前的几份报告表明HIV感染可能与自然生育能力下降有关,我们的目标还包括评估进入我们ICSI计划的HIV-1感染女性的生育状况。
严格执行法国关于在感染HIV-1的女性中使用辅助生殖方案的法律。纳入标准为无正在进行的疾病、CD4(+)细胞计数>200个细胞/mm³以及稳定的HIV-1 RNA水平。由于感染HIV-1的女性在进行ICSI时的平均年龄高于未感染HIV的女性总体组,我们将感染HIV-1的女性(第一组)的结果数据与在年龄和卵泡采集期方面匹配的未感染HIV-1的女性组(第二组)以及在我们机构接受ICSI的女性总体组(第三组)进行了比较。
对29名感染HIV-1的女性共进行了66次卵巢刺激。感染女性取消周期的百分比高于匹配的对照组(15.2%对4.9%,P<0.05)。感染女性的卵巢刺激持续时间(13.3天对11.7天,P<0.05)和注射的重组促卵泡素量(2898 IU对2429 IU,P<0.001)也更高。所有组中回收的卵母细胞、成熟卵母细胞和胚胎数量以及胚胎质量相似。感染女性的受精率高于匹配的对照组(67%对60%,P<0.01)。尽管为了尽量减少多胎妊娠,在感染HIV-1的组中故意限制了移植的胚胎数量(2.0对2.4,无显著差异),但第一组和第二组的妊娠率没有显著差异(16.1%对19.6%)。
这一系列在感染HIV-1的女性中进行的ICSI周期的初步结果表明,与匹配的血清学阴性女性相比,实现最佳卵巢刺激略为困难。然而,当满足卵母细胞采集标准时,ICSI结果与年龄匹配的对照组相似。